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ABSTRACT
Introduction: Empagliflozin is an SGLT-2 inhi-
bitor (SGLT-2i) which belongs to a new class of
hypoglycemic drugs with the unique property
of decreasing blood glucose independently from
insulin, through an increase in glycosuria. In
addition to decreasing cardiovascular morbidity
and mortality, empagliflozin has nephropro-
tective properties in high cardiovascular risk
patients with type 2 diabetes. Decreased hyper-
filtration and shifting towards more favorable
renal fuel energetics with improved renal oxy-
genation may explain some of these properties.
With this study, we propose to explore the
effects of empagliflozin on renal tissue oxy-
genation using blood oxygenation level-depen-
dent magnetic resonance imaging (BOLD-MRI).
Methods: This is a double-blind, randomized,
placebo-controlled study examining the acute
and chronic renal effects of empagliflozin
10 mg. The primary outcome is the effects of
empagliflozin on renal tissue oxygenation as
measured by BOLD-MRI. The secondary out-
comes include the effects of empagliflozin on
tubular function, 24 h blood pressure control,
and the influence of body mass index (BMI) on
the renal response to empagliflozin. Fifteen
normal weight, 15 overweight, and 15 obese
non-diabetic subjects (men and women) will be
recruited. Each participant will undergo 24 h
urine collections and blood pressure measure-
ments on day - 1, followed by an investigation
day at the study center with blood and urine
sampling and renal BOLD-MRI measurements
before and 180 min after the administration of
10 mg empagliflozin or placebo. This sequence
of measurements will be repeated after 1 month
of a daily empagliflozin or placebo intake. To
investigate renal oxygenation, the renal cortical
and medullary R2*, as a marker of oxygenation,
will be assessed by BOLD-MRI under standard-
ized hydration conditions: the higher R2*, the
lower oxygenation.
Conclusion: SGLT-2 inhibitors have a profound
effect on renal physiology. This is an important
study that will explore for the first time whether
inhibiting SGLT-2 with empagliflozin in heal-
thy volunteers affects renal tissue oxygenation
as determined by BOLD-MRI.
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INTRODUCTION
SGLT-2 inhibitors (SGLT-2i) belong to a new
class of hypoglycemic drugs with the unique
property of decreasing blood glucose indepen-
dently from insulin, through an increase in
glycosuria. Following the results of the EMPA-
REG trial [1, 2], the nephrology community has
expressed a considerable interest in this new
antidiabetic class [3]. Diabetic kidney disease is
now the main cause of end-stage renal disease
in developed countries and new therapies have
been lacking for more than 15 years since the
milestone trials with renin–angiotensin system
blockers [4–6].
In high cardiovascular risk patients with type
2 diabetes (T2D), empagliflozin decreases car-
diovascular mortality, death from any cause,
and hospitalization for heart failure [1]. In
addition, empagliflozin slows the eGFR (esti-
mated glomerular filtration rate) decline,
decreases the progression of albuminuria, and
decreases cardiovascular mortality in albumin-
uric subjects [2]. Following these results from
the EMPA-REG trial, the recommended phar-
macological approach of people with T2D and
established cardiovascular disease has been
revised [7, 8].
The mechanisms of nephroprotection with
SGLT-2i are under investigation. These drugs
inhibit partially the sodium glucose transporter
2 (SGLT-2) in healthy volunteers and in T2D
and shift the threshold for renal glucose excre-
tion to lower levels [9]. SGLT-2 transporters are
expressed at the luminal membrane of the
proximal tubule and are involved in the reab-
sorption of 90% of filtered glucose [10].
Through SGLT-2, glucose is transported with
sodium (1:1), driven by a concentration gradi-
ent induced by the active Na/K ATPase transport
of sodium at the basolateral membrane. Overall
these glucose and sodium transports participate
in the high metabolic activity of the proximal
tubule; therefore, interacting with them may
change the oxygen requirements.
The current main hypotheses for the mech-
anisms of nephroprotection with SGLT-2i are
(1) decreased hyperfiltration due to a restored
tubular glomerular feedback; (2) shift towards
more favorable renal fuel energetics with
improved renal oxygenation [11–14]. Indeed,
adequate renal tissue oxygenation is critical for
the maintenance of normal renal function [15]
and hypoxia increases the susceptibility to acute
and chronic renal injury [16]. Renal tissue
hypoxia can be induced by oxidative stress,
altered renal hemodynamics, increased GFR,
tubular hypertrophy, or increased transport
activity, factors that are all possibly encoun-
tered in diabetes. Type 2 diabetes is associated
with lower medullary pO2 levels (measured with
blood oxygenation level-dependent magnetic
resonance imaging, BOLD-MRI) as compared to
age-matched healthy controls [17–19]. Previous
studies in humans have strongly suggested that
tubular sodium reabsorption is the most
important factor determining renal tissue oxy-
genation. Thus a reduction in proximal sodium
reabsorption induced by inhibition of proximal
SGLT-2 could also be associated with a favorable
change in renal tissue oxygenation.
Since directly quantifying intrarenal blood
flow or oxygenation is not possible in clinical
practice, the detection of renal hypoxia remains
indirect [15]. New forms of technology such as
BOLD-MRI allow one to assess renal tissue
oxygenation non-invasively [18]. The measure-
ments can be repeated several times in the same
person without the need to administer contrast
products, making BOLD-MRI an ideal tool to
measure medication-induced changes in renal
oxygenation. This technique has been used
successfully in the Nephrology Department of
the University Hospital in Lausanne for more
than 5 years, as illustrated by several publica-
tions [19–21]. We have shown previously that a
decrease in sodium intake in healthy subjects
and hypertensive patients increases renal tissue
oxygenation [20]. Similarly, the administration
of furosemide has been associated with a
decrease in sodium reabsorption and an
increase in renal tissue oxygenation.
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With this study, we propose to explore the
effects of empagliflozin on renal tissue oxy-
genation. Our hypothesis is that SGLT-2 inhi-
bition decreases renal cortical energy
requirements with consequently an increase in
renal tissue oxygenation. In this first study we
chose not to investigate people with diabetes to
avoid the confounding factor of blood glucose
fluctuations on the BOLD-MRI signal [19]. Fur-
thermore different weight groups will be
examined for the assessment of the influence of
BMI (body mass index) and baseline GFR on the
renal response to SGLT-2i.
SGLT-2 inhibition does not induce hypo-
glycemia unless it is given with insulin or an
insulin secretagogue. The main side effects are
associated with the osmotic diuresis/glycosuria,
i.e., increased rate of genital infection and
increased risk of hypovolemia. The risk of uri-
nary tract infection is only marginally
increased. Recently rare cases (\0.1%) of eug-
lycemic ketoacidosis have been reported mainly
in insulin-treated subjects undergoing surgery
and fasting [22]. Thus, subjects taking these
drugs need to be informed of the side effects,
their symptoms, treatment, and preventive
measures
Primary Objective
To investigate the acute and chronic effects of
SGLT-2 inhibition with empagliflozin on renal
tissue oxygenation as measured by BOLD-MRI.
Secondary Objectives
To evaluate the effects of empagliflozin after
4 weeks treatment on:
1. Diurnal and nocturnal glucose, sodium,
potassium, uric acid, calcium, phosphate,
and lithium clearances
2. Erythropoietin and hematocrit
3. Renal resistance indexes and renal volume
4. 24 h blood pressure measurements, diurnal
and nocturnal blood pressure and pulse
pressure
5. The effect of BMI on renal reponses to
empagliflozin
METHODS
Overall Design, Investigational Plan,
and Study Population
This study is a double-blind, randomized, pla-
cebo-controlled study that will examine per
protocol the acute and chronic renal effects of
empagliflozin 10 mg in healthy non-medicated
volunteers.
Fifteen normal weight (BMI 18.5–24.9 kg/
m2), 15 overweight (BMI 25–29.9 kg/m2), and
15 obese (BMI C 30 kg/m2) non-diabetic sub-
jects (men and women) will be recruited with
the following criteria: age 18–50 years,
HbA1c\ 6.5%, plasma fasting glu-
cose\7.0 mmol/l, plasma glucose level at 2
hours of oral glucose tolerance test (OGTT)\
11.1 mmol/l, eGFR[60 ml/min (estimated by
the creatinine-based CKD-EPI equation), urine
albumin/creatinine ratio\ 3.3 mg/mmol, nor-
mal ultrasound, normal urine dipstick, normal
hematology and chemistry results. Each partic-
ipant visits the study center on seven occasions,
following the routine screening visit which
includes a signed informed consent followed by
a complete medical history, baseline physical
examination, blood test, urine dipstick, 75 g
oral glucose tolerance test (OGTT), and a renal
ultrasound. In the absence of exclusion criteria,
each weight group will be randomized to pla-
cebo (n = 5) and empagliflozin (n = 10). Thus,
in total, 30 subjects will be randomized to
empagliflozin and 15 subjects to placebo.
The study begins with a 24 h ambulatory
blood pressure monitoring and 24 h urine col-
lection. On the following morning, the volun-
teer stays at the study center for a day. During
the first study day (acute phase), serial blood
and urine collections and two renal BOLD-MRIs
before and after the oral administration of
empagliflozin 10 mg will be done. At comple-
tion of the study day, the volunteer leaves the
center and takes a pill of placebo or empagli-
flozin each day for 28–30 days (depending on
the availability of research MRI resource and
menstrual cycle for women). Women will be
examined during the follicular phase of the
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cycle or during the first 7 days of the contra-
ceptive pill.
The day before the intake of the study drug
(placebo or empagliflozin), the volunteer will
undergo the same sequence of measurements
during 2 days as described above (chronic
phase). The overall study design is illustrated
(Fig. 1) with detailed measurements at each visit
(Table 1).
The inclusion and exclusion criteria are
summarized below.
Inclusion Criteria
• Normal weight (BMI 19–24.9 kg/m2), over-
weight (BMI 25–30 kg/m2), or obesity
(BMI[30 kg/m2).
• Men and women (with a negative pregnancy
test) during the follicular phase of the men-
strual cycle. All groups will have a balanced
number of men and women.
• OGTT/HbA1C: normal or prediabetes.
• eGFR[ 60 ml/min, albumin/creatinine
ratio\ 3.3 mg/mmol (\ 30 mg/g).
• Signed consent form.
• Normal renal ultrasound.
• Normal urine dipstick.
• Normal hematology and chemistry results.
Exclusion Criteria
• Chronic medication
• NSAID treatment
• Former bariatric surgery
• Age\18 years or[50 years
• At risk of dehydration or hypotension
• Past history of recurrent genital or urinary
tract infections
• Contraindication for MR imaging (pace-
maker or other implanted metallic device,
claustrophobia)
• Pregnancy
Inclusion
Blood tests ,oral glucose tolerance test
Urine sampling
Renal ultrasound
Blood sampling (AP-S240)
Bold MRI (AP-B0)
-240 min, supine
hydration
Empagliﬂozin 10mg
90min
Bold MRI
(AP-B180)
90min
AP T90 :
Urine and blood
sampling
(AP-U90; AP-S90)
AP D-1:
24h urine collecon (AP-U24)
24h blood pressure measurement (AP-PA24)
Urine and 
blood sampling
(AP-U180; AP-S180)
AP
AP T180:
Urine and blood sampling (CP U0 CP-S0)
Bold MRI (CP-B0)
-240min supine,
hydration
Empagliﬂozin 10mg
90min
Bold MRI
90min
CP T90 :
Urine and blood
sampling
(CP-U90; CP-S90)
CP D-1:
24h urine collecon (CP-U24)
24h blood pressure measurement (CP-PA24)
Renal ultrasound (CP)
Urine and
blood sampling
(CP-U180; CP-S180)
CP
CP T180:
Empagliﬂozin 
10mg
4 weeks qd
Acute phase (AP) Chronic Phase (CP)
•Pill count
•Blood pressure 
measurement
•weight
Intermediary visits
Week 1 Week 2 Week 3 Week 4PA PC
1 2 3 4
1 2 3
Phone contacts (4)
Int. visits (3)
Urine and blood sampling
(AP-S0 and AP-U0)
Blood sampling (CP-S240)
AP CP
Fig. 1 Flowchart of the study
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• Sustained systolic blood pres-
sure[150 mmHg or diastolic blood
pressure[95 mmHg
• Current or past psychiatric disease including
history of substance abuse (drug, alcohol,
medication)
Sample Size
The goal of this study is to examine the acute
and chronic effects of empagliflozin on varia-
tions of renal tissue oxygenation, blood pres-
sure, biochemical and clinical parameters from
baseline, in comparison with placebo.
The primary goal will test the hypothesis
that SGLT-2 inhibition will improve renal oxy-
genation with a decrease of medullary R2*, as a
marker of increased oxygenation. To determine
the minimum sample size needed to make
adequate testing of the effect, the sample
computation was based on data available from
the study by Pruijm et al. [19]. The mean (± SD)
baseline medullary R2* in healthy subject was
29.3 (± 2.4). Assuming that the treatment will
improve the oxygenation by 10%, the sample
size required to demonstrate a significant effect
with a power of 90% and an a type I error of 5%
is 15 subjects per group. However we plan to
randomize a total of 45 subjects: 15 in the pla-
cebo group and 30 subjects with empagliflozin.
The power of the study to detect a significant
difference between the placebo and treatment
arm is then 97%.
One secondary goal will be to examine the
influence of body weight on the renal response
to empagliflozin. As hyperfiltration increases
with increased BMI, we plan to examine three
groups, namely normal weight, overweight, and
obese individuals. This part of the study is
completely exploratory. However, assuming
that the treatment will improve the
Table 1 Detailed measurements performed at each visit
Screening Acute phase (AP) Chronic phase (CP)
D-
1
T-
240
T0 T90 T180 D-
1
T-
240
T0 T90 T180
Signed consent form X
Medical history X
Physical examination X
Oral glucose tolerance test X
Renal ultrasound X X
24 h ambulatory blood pressure
measurement
X X
BOLD-MRI X X X X
Pregnancy test X X X
Blood chemistry X X X X X X X X X
Blood count X X X X X X X X X
Urine dipstick X
24 h urine collection X X
Urine chemistry X X X X X X
Urinary exosomes X X X
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oxygenation by 2.5%, 5%, and 10%, respec-
tively, in the normal weight, overweight, and
obese groups, sample size calculation using a
two-way analysis of variance (ANOVA) with the
treatment (2 levels) as a row factor and the BMI
groups (3 levels) as a column factor showed that
a minimal sample size of 5 subjects by cell (to-
tal = 5 9 6 = 30) will be needed to show the
treatment effect difference between the BMI
groups with a power of 80% and an a type I
error of 5%. The calculated sample size for the
primary goal will then cover the secondary goal.
Because interindividual values of renal
parameters may vary, we will also analyze the
intraindividual variations of renal parameters
compared to baseline values. We have per-
formed similar studies in the past with serial
measurements in the same subject exposed to
different treatment phases [23, 24]. Although a
small number of individuals were examined in
these studies (n = 9–16), statistical significance
was reached for the change in renal parameters.
In addition, repeated measurements from the
placebo group will examine the reproducibility
of the method.
Enrollment
An announcement for recruitment is posted at
the University Hospital Center (CHUV) in Lau-
sanne, Switzerland and is visible on the web
page of the institution. The study center is
located in the Nephrology and Hypertension
Service of the CHUV. After contacting the study
nurse, volunteers receive an information sheet
which includes detailed information on the
study protocol, side effects, their symptoms,
treatment, and preventive measures, and they
are invited to an information visit. Then, a
minimum of 48 h is requested before confirm-
ing their interest and planning the screening
visit.
Screening
The screening visit begins after signing the
written informed consent. Screening includes a
complete medical history to confirm the par-
ticipant’s eligibility as determined by the
inclusion and exclusion criteria, a physical
examination, a blood test, a urine dipstick, an
OGTT, and a renal ultrasound. A decision as to
the participant’s eligibility is taken as soon as all
the results are available. One week to 2 months
after the screening visit, the volunteer is inclu-
ded in the first day of the acute phase study
(APJD-1) and a month later in the chronic phase
study. At that time they also receive two bottles
(day and night) for the 24 h urine collection
and instructions to follow for the investigation
days (APD-1, AP, CPD-1, CP) and a calendar to
write down when they take the pills.
Randomization
Randomization procedure is done by the hos-
pital’s pharmacy the first day of the acute phase
(APD-1). Empagliflozin 10 mg or placebo pills
are identical in size and stored in similar boxes
containing 30 pills.
Drug Administration
The first pill of empagliflozin 10 mg or placebo
is administered by the study team right after the
first BOLD-MRI with a glass of water. The par-
ticipant is instructed to take a pill each day at
the same time until the last day of the study
(between day 28 and 30). The participants are
asked to write down on a calendar every day at
what time they take the pill and any comment
they may have. At each visit, the calendar and
pill count are checked to confirm drug compli-
ance. At the end of the study, the participants
return the box and its unused product that will
be destroyed on-site.
Study Visits and Procedures
Volunteers undergo two examination phases:
the acute phase (AP) and the chronic phase
(CP).
Similar examinations are performed for the
acute phase (AP: D-1, T-240, T0, T90, and T180)
and the chronic phase (CP: D-1, T-240, T0, T90,
T180). During the chronic phase evaluation, an
additional renal ultrasound is performed as at
screening.
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D - 1 (day - 1): volunteers visit the study
center briefly at 8.30 a.m. to be equipped with
the 24 h ambulatory blood pressure measure-
ment Diasys device. Women have a pregnancy
test. A renal ultrasound is performed at the
chronic phase.
The rest of the day is spent routinely out of
the center. Measurements include:
• A 24 h urine collection. Diurnal and noctur-
nal urine are collected separately to measure
glucose, sodium, potassium, uric acid, cal-
cium, phosphate, and endogenous lithium.
Participants are instructed not to smoke or
drink alcohol or have any caffeine-contain-
ing beverages during that day.
• 24 h ambulatory blood pressure measure-
ments: on the day of the 24 h urine collec-
tion, 24 h ambulatory blood pressure is
recorded, with measurements performed at
20-min intervals from 8 a.m. to 10 p.m., and
at 30-min intervals from 10 p.m. to 8 a.m.
(Diasys, Physicor, Geneva, Switzerland). This
device has been validated by the British
Hypertension Society and was rated B/B.
• Renal ultrasound (only at screening and
chronic phase evaluation). Renal ultra-
sounds are performed according to a stan-
dard procedure [25] for the screening of renal
abnormalities at inclusion and for the mea-
surements of renal resistance indexes. The
Aplio XG device (Toshiba Medical Systems,
Volketswik, Switzerland) will be used for
ultrasound examination and performed by
the same experienced operator in the study
center.
• For women only: a plasma pregnancy test.
AP/CP following D - 1 (T - 240, T0, T90,
T180):
• The following day, the participant has a light
breakfast at 7 a.m. at home.
• At arrival at 9 a.m. at the study center, after
urine voiding, a peripheral venous catheter
will be inserted for serial blood sampling.
Volunteers will be hydrated initially with
5 ml/kg of oral water followed by 3 ml/kg/h.
An identical oral hydration protocol is used
for each participant on the day of each
BOLD-MRI measurement to avoid as much
as possible differences in renal perfusion
induced by differences in volume status.
• The volunteer remains until 5 p.m. in the
research center to undergo two BOLD-MRIs,
urine and blood sampling. Peak levels of
empagliflozin are reached 1.5–3 h after a
single dose [26]. Each volunteer will thus
undergo renal BOLD-MRI measurements
before (T0) and 180 min (T180) after the
first pill of empagliflozin 10 mg/placebo.
Urine and blood sampling will be performed
at T-240, T0, T90, and T180. BOLD-MRI
measurements of the kidneys will be per-
formed at T0 and T180 at the Department of
Radiology at the University Hospital CHUV,
Lausanne. The research nurse escorts the
participant to the BOLD-MRI and stays with
him during the whole procedure which lasts
around 30 min.
All tests are repeated after 4 weeks of treat-
ment with empagliflozin (chronic phase).
During the 4 weeks of treatment, volunteers
have weekly telephone contacts with the
research nurse in order to monitor the course of
the treatment and identify side effects. Weekly
intermediary visits are scheduled for blood
pressure, weight measurements, and pill counts.
The last pill will be taken right after the CP
T0 renal BOLD-MRI measurement.
Pharmacovigilance
All adverse events are reported and graded by
the co-investigator physician in charge of the
participant. All non-serious adverse events (AE)
are recorded at each visit. Each volunteer carries
a volunteer card indicating his randomization
number, the name and number of the study, the
name of the principal investigator, the name of
the drug (empagliflozin or placebo), and the
emergency phone number.
In case of serious adverse event (SAE), the
volunteer will call the emergency number on
the card and reach the nephrologist on duty.
The nephrologist will decide if emergency
management and suspending the treatment are
necessary and inform the co-investigator in
charge of the study as soon as possible. The co-
investigator will evaluate the necessity of
breaking the code. If breaking the code is nec-
essary, the co-investigator will immediately
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inform the principal investigator who keeps the
randomization code in one envelope per
volunteer.
Trial Monitoring
Monitoring is overseen by the clinical trial unit
(CTU) according to a risk-adapted monitoring
strategy described in a study-specific monitor-
ing plan and according to standard operating
procedures of the Lausanne CTU. Basically, a
site initiation visit, routine monitoring visits,
and a close-out visit will take place. The CTU’s
role includes checking that all approvals are in
place before the start of the trial, the quality,
security, and observation of data protection
law, ensuring the trial is conducted in accor-
dance with the International Conference on
Harmonisation (ICH) Good Clinical Practice
(GCP), and controlling of the adherence to the
study protocol.
Analysis
Data analysis will be performed using Stata
Software (StataCorp. 2015. Stata Statistical
Software: Release 14. College Station, TX: Sta-
taCorp LP). Summary data will be presented as
mean (± SD) for continuous variables and as
numbers (percent) for categorical variables. To
investigate the acute and chronic effects of the
SGLT-2 inhibition on the improvement of renal
oxygenation, the renal cortical and medullary
R2*, as a marker of oxygenation will be assessed
using a mixed-effect linear model. The varia-
tions of parameters during the study and the
influence of clinical cofactors (age, sex, BMI,
etc.) will be tested as well as the interactions
between the BMI groups and treatment and
phase. A level of significance less than 0.05 will
be used in this study. An analysis of sensitivity
to missing values will be performed. First, an
intent-to-treat analysis including all patients
will be performed. Secondly we will run multi-
ple imputations using a Markov chain Monte
Carlo single chain method based on patient
baseline characteristics to create M imputed
data sets. Analysis will be performed separately
on each imputationm = 1,… ,M and the results
obtained from the M completed data analyses
will be combined into a single multiple-impu-
tation result which will be compared to results
from no imputed data.
Data collected in the trial will be analyzed
and submitted for publication as soon as possi-
ble. Data analysis will be exclusively performed
by the authors of the study with their free
interpretation.
BOLD-MRI Analysis
MR images are acquired using one coronal slice
on a 3-T whole-body MR system (Magnetom
Prisma, Siemens Medical Systems, Erlangen,
Germany), using previously described MR
parameters (Pruijm, Plos ONE 2014). In brief, 12
T2*-weighted images are collected for the coro-
nal slice within a single breath-hold of 12.4 s (in
expiration) using a modified multi echo data
image combination sequence (MEDIC) for
BOLD analysis. This procedure is repeated 10
times.
All data are saved on CDs and stored in a
secured place at the Nephrology and Hyper-
tension Department of the study center. Images
will be imported for further analysis in Matlab
7.11 (The MathWorks Inc., Natick, MA, USA)
[27]. R2* maps will be calculated voxel by voxel
using the linear least-squares fit of the loga-
rithm of the signal. The 12-layer concentric
objects method (TLCO) will be used to analyze
the images. With this technique, an automatic
algorithm divides the selected renal par-
enchyma of each coronal slice into 12 layers of
equal thickness. By averaging the R2* values per
layer of all four coronal slices, one obtains the
mean R2* of each layer for the kidney. The
mean R2* value of the outer three layers of the
two kidneys will be used as a proxy of renal
cortical oxygenation, and the mean R2* value of
the inner (8th–10th) layers will be used to
report medullary oxygenation. Renal blood flow
in the main renal arteries will be measured
using phase contrast MRI.
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Study Strengths and Limitations
• This is the first study to examine the acute
and chronic effects of empagliflozin on renal
oxygenation using BOLD-MRI.
• The randomized, placebo-controlled design
will clearly examine the hypothesis that
empagliflozin may influence renal
oxygenation.
• The measurement of important variables
such as 24 h blood pressure control, tubular
function, and BMI will examine their influ-
ence on the renal responses to empagliflozin.
• The fact that non-diabetic individuals are
examined may decrease the power to iden-
tify a renal effect of empagliflozin as glyco-
suria with SGLT-2i is less pronounced than
in type 2 diabetes.
• BOLD-MRI measurements provide an indi-
rect quantification of renal oxygenation.
Ethics and Dissemination
The research project is carried out in accordance
with the research plan and the principles of the
current version of the Declaration of Helsinki
(DoH), the Essentials of Good Epidemiological
Practice issued by Public Health Schweiz (EGEP),
Swiss law, and Swiss regulatory authority
requirements as applicable. The local ethics
committee (EC) and regulatory authorities are
informed about the project start and termina-
tion. The protocol was accepted by the local
ethical committee (Commission cantonale
d’e´thique de la recherche sur l’eˆtre humain,
protocol number CER-VD 2016-00099) and
SwissMedics (no. 2016DR2171), the national
drug regulation authority.
The participant receives written and oral
information from the co-investigator physician
before the screening visit. The participant has at
least 48 h to think before planning the screen-
ing visit, if he is still interested in the study. He
is invited to ask all questions that may arise
before or at the screening visit. Then he is asked
to sign the informed consent document. A copy
of the signed document is given to the patient
and the original placed in the investigator site
file. The participant may withdraw from the
trial at any time by revoking his consent with-
out any reason.
Data collected in the trial will be analyzed
and submitted for publication as soon as possi-
ble. Data analysis will be exclusively performed
by the authors of the study with their free
interpretation.
CONCLUSION
SGLT-2 inhibitors have a profound effect on
renal physiology with nephroprotective effects
in patients with T2D and established
macrovascular disease. Different hypotheses on
the mechanisms of nephroprotection are cur-
rently under investigation. A favorable effect on
renal oxygenation has been proposed as a con-
tributing factor. This randomized controlled
study will examine for the first time whether
acute or chronic inhibition of SGLT-2 with
empagliflozin in healthy volunteers of different
weight categories affects renal tissue oxygena-
tion as determined by BOLD-MRI. The results of
this study should lay the foundation for future
studies exploring the effects of SGLT-2 inhibi-
tion on renal oxygenation in a population at
risk from nephropathy using BOLD-MRI.
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